Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.
Positron emission tomography using 68gallium-labeled ligands of the prostate-specific membrane antigen is accurate, reproducible, and safe in localizing biochemically recurrent prostate cancer, according to the results of a prospective trial.
Research reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, shows that the incidence of prostate cancer and associated mortality has generally declined or remained steady in most of the countries with available data.
Supplementing androgen deprivation therapy with apalutamide improves metastasis-free survival in patients with the luminal and basal subtypes of nonmetastatic castration-resistant prostate cancer, indicates an analysis of the randomized SPARTAN trial.
Among men initiating abiraterone acetate for advanced prostate cancer, the mortality risk may be higher for those with versus without pre-existing cardiovascular disease, suggests a real-world study presented at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA.
Patients who receive carbon ion radiotherapy for localized prostate cancer have a significantly lower risk for subsequent primary cancers than those treated with photon radiotherapy or surgery, retrospective study data suggest.
Adding docetaxel chemotherapy to standard long-term androgen suppression plus radiotherapy significantly improves survival in patients with high-risk nonmetastatic prostate cancer, show data from the NRG Oncology RTOG 0521 study.
Men positive for androgen receptor splice variant 7 in circulating tumor cells derive little benefit from abiraterone or enzalutamide in the treatment of metastatic castration-resistant prostate cancer, US researchers report.
A Danish study has found no protective effect of low-dose aspirin taken after diagnosis on prostate cancer-specific mortality, while South Korean research has identified a link between long-term use of the nonsteroidal anti-inflammatory drug and a reduced risk for incident lung cancer.
A phase III trial investigating the efficacy of PROSTVAC, a viral vector–based immunotherapy, in the treatment of metastatic castration-resistant prostate cancer was stopped early due to a lack of positive results, say researchers.
Intense androgen deprivation therapy before radical prostatectomy benefits some patients with locally advanced prostate cancer, report researchers who found that results may be better with a four-drug than a two-drug regimen.
Hypofractionated radiotherapy is similar to conventional radiotherapy when it comes to health-related quality of life in men with low-risk prostate cancer, according to the RTOG 0415 phase III randomized controlled trial.
Men with nonmetastatic, castration-resistant prostate cancer receiving enzalutamide maintain their low baseline pain levels and prostate cancer symptom burden and report high health-related quality of life, indicates a patient-reported outcomes analysis of the phase III PROSPER study.
Combining radium-223 with abiraterone acetate plus prednisone or prednisolone is not recommended for patients with castration-resistant prostate cancer and bone metastases, ERA 223 researchers report.
The combination of nivolumab and ipilimumab has antitumor activity in men with metastatic castration-resistant prostate cancer, suggest CheckMate 650 data.
Supplementing androgen deprivation therapy with enzalutamide delays radiologic progression in men with metastatic castration-sensitive prostate cancer, indicate phase III trial findings presented at the 2019 ASCO Genitourinary Cancers Symposium.
Addition of the androgen receptor antagonist darolutamide to androgen deprivation therapy improves metastasis-free survival in patients with castration-resistant prostate cancer, indicate ARAMIS trial results.
Results from an expansion cohort add support for the use of lutetium-177-prostate-specific membrane antigen-617 in heavily pretreated men with metastatic castration-resistant prostate cancer.
An analysis of a US database shows that Black individuals who receive abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer have better overall survival than their White counterparts.